🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSemaglutide and MASH — my results so far

Semaglutide and MASH — my results so far

BenResearch_OR Wed, Jan 21, 2026 at 8:30 PM 6 replies 855 viewsPage 1 of 2
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Jan 21, 2026 at 8:30 PM#1

Started at 0.25mg with a fairly bad first week, held each step the full four weeks, and I am now at 1mg with no side effects worth naming.

For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.

What I am after is what the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss.

Not looking for reassurance. Looking for the part I have got wrong.

35 5julia.endo, JessicaM_2024, TomFromTexas and 32 others
Reply Quote Save Share Report
TirzTom
Senior Member
2,789
9,876
Feb 2024
Florida
Online
Jan 21, 2026 at 8:55 PM#2

Answering the narrow version, because the broad one does not have a single answer. The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

34 4tom_AK, josh_phd_bmore, roxy_nash and 31 others
Reply Quote Save Share Report
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Jan 21, 2026 at 9:20 PM#3
TirzTom said:
The dose-response is real but shallow at the top.

No disagreement with TirzTom. One condition attached. Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

33 3Dr.SleepRoch, laura_annarbor, JenMemphis and 30 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
patPC_UT
Member
212
890
Nov 2024
Park City, UT
Jan 21, 2026 at 9:45 PM#4
BenResearch_OR said:
Started at 0.25mg with a fairly bad first week, held each step the full four weeks, and I am now at 1mg with no side effects worth naming.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

32 2JessicaM_2024, TomFromTexas, mike.trainer_LA and 29 others
Reply Quote Save Share Report
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
Jan 22, 2026 at 12:01 AM#5

From the other side of the consultation, briefly.

BenResearch_OR said:
...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

31 1B12Beth, RickReta_CO, PharmHunterJen and 28 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register